Drug Profile

Tasipimidine - Orion

Alternative Names: ODM-105

Latest Information Update: 06 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orion
Class 2 ring heterocyclic compounds; Behavioural disorder therapies; Imidazoles; Small molecules
Mechanism of Action Alpha 2a adrenergic receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Insomnia
No development reported Psychiatric disorders

Most Recent Events

30 Sep 2025 Efficacy and adverse event data from the phase II UNITAS trial in Insomnia released by Orion Pharma
28 Oct 2024 No recent reports of development identified for phase-I development in Psychiatric-disorders in USA
28 Jul 2023 Phase-II clinical trials in Insomnia in Finland (unspecified route) (ISRCTN35042256) (EudraCT2022-502483-21-00)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com